Celecoxib May Help Prevent Colorectal Cancer in High Risk Patients

Armen Hareyan's picture

Colorectal Cancer and COX-2

During the past year, the study of the potential use of COX-2 (cyclooxygenase-2) inhibitors to prevent colorectal and breast cancer has come under intense scrutiny. Recent research questioned the safety of these medicines as pain relievers, which was the initial indication, as well as for chemoprevention of cancer. Now, the latest data show that COX-2 inhibitors are highly effective in preventing pre-malignant tumors of the colon, and therefore may be useful in preventing colorectal cancer among high-risk patients.


According to two studies presented today at the 97th Annual Meeting of the American Association for Cancer Research, the over-expression of the COX-2 enzyme is related to the growth and spread of colorectal tumors. COX-2 inhibitors may reduce the occurrence of the precursor, colorectal adenomas (benign tumors) in patients with a family history of the disease, as well as the development of sporadic colorectal tumors.

Celecoxib reduces sporadic colorectal adenomas: Results from the Adenoma Prevention with Celecoxib (APC) trial.: Abstract No.CP-3

Investigators from the Adenoma Prevention with Celecoxib Study (APC) enrolled 2,035 patients to a randomized, double-blind trial of the COX-2 inhibitor, celecoxib (Celebrex